Introducing the latest JUVÉDERM® innovation  >
EXPAND TO SEE ALL ALLERGAN BRANDS +
For Us Healthcare Professionals
Important Safety Information Patient Safety Information + Directions for use + FOR US PATIENTS Contact Us Set up Account
X
COVID-19 SUPPORT
During this uncertain time, one thing remains certain—our commitment to supporting you.
Click here for COVID-19 resources for your practice.
X
Product Information Training Practice resources Ordering Rewards Results

FOR US HEALTHCARE PROFESSIONALS

PRODUCT INFORMATION TRAINING PRACTICE RESOURCES ORDERING REWARDS RESULTS
Important Safety Information Patient Safety Information Directions for Use FOR US PATIENTS Contact Us Set Up Account
×
BOTOX® COSMETIC
(onabotulinumtoxinA)
KYBELLA®
(deoxycholic acid) injection 10 mg/ml
COOLSCULPTING®
LATISSE®
(bimatoprost ophthalmic solution) 0.03%
NATRELLE®
SKINMEDICA®
×
  • JUVÉDERM® ULTRA XC
  • JUVÉDERM® ULTRA PLUS XC
  • JUVÉDERM® ULTRA
  • JUVÉDERM® ULTRA PLUS
  • JUVÉDERM VOLUMA® XC
  • JUVÉDERM VOLBELLA® XC
  • JUVÉDERM VOLLURE™ XC
×
  • JUVÉDERM® ULTRA XC
  • JUVÉDERM® ULTRA PLUS XC
  • JUVÉDERM® ULTRA
  • JUVÉDERM® ULTRA PLUS
  • JUVÉDERM VOLUMA® XC
  • JUVÉDERM VOLBELLA® XC
  • JUVÉDERM VOLLURE™ XC
Read More +
JUVÉDERM® INJECTABLE GEL FILLERS INDICATIONS
The JUVÉDERM® Collection of Fillers includes JUVÉDERM VOLUMA® XC, JUVÉDERM VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, JUVÉDERM® Ultra XC, and JUVÉDERM VOLBELLA® XC. JUVÉDERM VOLUMA® XC is for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit in adults over the age of 21. JUVÉDERM VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC are for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). JUVÉDERM® Ultra XC is also for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVÉDERM VOLBELLA® XC is for injection into the lips for lip augmentation and for correction of perioral rhytids in adults over the age of 21.
Actual patient treated with JUVÉDERM VOLLURE™ XC. Results may vary.
tailored Treatment for
Moderate to Severe
Facial Wrinkles and Folds
Actual patient treated with JUVÉDERM®  Ultra Plus XC and JUVÉDERM® Ultra XC. Results may vary.
tailored Treatment for
Moderate to Severe
Facial Wrinkles and Folds
JUVÉDERM VOLLURE™ XC is the first and only FDA-approved filler to correct moderate to severe facial wrinkles and folds for up to 18 months.1,*
add subtle volume to
SMOOTH facial
wrinkles and folds1,2
  • • High patient satisfaction through 18 months1
  • • Tailored with a unique balance of gel properties1,2
LASTS UP TO
18 MONTHS1,*
*With optimal treatment.
JUVÉDERM® Ultra XC
lasts UP TO 1 year1,2,*
*With optimal treatment.
JUVÉDERM® Ultra Plus XC
lasts beyonD 1 year3,*
*With optimal treatment.
Distinct formulations for moderate to severe facial wrinkles and folds
JUVÉDERM® Ultra XC is a highly cross-linked gel.1
JUVÉDERM® Ultra Plus XC is a robust formulation with a higher degree of cross-linking.3
SEE THE DIFFERENCE
Karla
BEFORE
AFTER 1 MONTH
karla-before karla-after
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.3 mL of JUVÉDERM VOLLURE™ XC was injected into facial wrinkles and folds.
Karla
Karla-Smile
BEFORE
AFTER 1 MONTH
karlasmile-before karlasmile-after
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 2.3 mL of JUVÉDERM VOLLURE™ XC was injected into facial wrinkles and folds.
Catherine, 40s
BEFORE
AFTER 1 MONTH
catherine-before catherine-after
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 3.75 mL of JUVÉDERM VOLLURE™ XC was injected into facial wrinkles and folds.
Catherine, 40s
Catherine-Smile
BEFORE
AFTER 1 MONTH
catherine-smile-before catherine-smile-after
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 1 month after treatment. A total of 3.75 mL of JUVÉDERM VOLLURE™ XC was injected into facial wrinkles and folds.
These photos are not of a clinical trial subject.
SEE THE DIFFERENCE
Abbey, 40s
BEFORE
AFTER 2 WEEKS
abbey-before abbey-after
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 weeks after treatment. A total of 2.2 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 1.0 mL of JUVÉDERM® Ultra XC was also injected into facial wrinkles and folds.
Karen
BEFORE
AFTER 1 MONTH
AT 1 YEAR
karen-before karen-after
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient who received a 3-syringe treatment with JUVÉDERM® Ultra XC for facial wrinkles and folds. One syringe = 1.0 mL of JUVÉDERM® Ultra XC.
Laura, 40s
BEFORE
AFTER 2 WEEKS
laura-before laura-after
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 weeks after treatment. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 2.2 mL of JUVÉDERM® Ultra XC was also injected into facial wrinkles and folds.
Lisa, 40s
BEFORE
AFTER 1 MONTH
AT 1 YEAR
lisa-before lisa-after
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient who received a 3-syringe treatment with JUVÉDERM® Ultra XC for facial wrinkles and folds. One syringe = 1.0 mL of JUVÉDERM® Ultra XC.
Jennifer, 50s
BEFORE
AFTER 2 WEEKS
jennifer-before jennifer-after
BEFOREAFTER
ZOOM
Actual patient. Results may vary.
Unretouched photos of paid patient taken before treatment and 2 weeks after treatment. A total of 2.0 mL of JUVÉDERM® Ultra Plus XC was injected into facial wrinkles and folds. A total of 1.0 mL of JUVÉDERM® Ultra XC was also injected into facial wrinkles and folds.
These photos are not of a clinical trial subject.
HIGH PATIENT SATISFACTION1,3
AT 6 MONTHS1

of patients were

VERY SATISFIED†
(n = 117)3
AT 18 MONTHS1

of patients were

VERY SATISFIED1,3,†
(n = 59)1,3
†Very satisfied was a score of 7 to 10 on a 0-to-10 scale.
watch injection training
The video reviews
  • • Patient assessment
  • • Injection technique
TRAIN ONLINE NOW  > TRAIN ONLINE NOW  >
watch injection training
THE VIDEO REVIEWS
  • • Unique gel properties
  • • Clinical study highlights
  • • Injection technique and tips
TRAIN ONLINE NOW  > TRAIN ONLINE NOW  >
Also approved for lip augmentation.1
LEARN MORE  >
<  midface
LIPS AND PERIORAL LINES  >
To download before-and-after photos,
visit allergan brandbox  >
References: 1. JUVÉDERM VOLLURE™ XC Directions for Use, 2017. 2. Pierre S, Liew S, Bernardin A. Basics of dermal filler rheology. Dermatol Surg. 2015;41(suppl 1):120S-126S. 3. Data on file, Allergan, October 26, 2015; CSR JUVÉDERM VOLLURE™ XC S17L-001 Final Report.
References: 1. JUVÉDERM® Ultra XC Directions for Use, 2017. 2. Pinsky MA, Thomas JA, Murphy DK, Walker PS; for JUVÉDERM® vs ZYPLAST® Nasolabial Fold Study Group. JUVÉDERM® injectable gel: A multicenter, double-blind, randomized study of safety and effectiveness. Aesthetic Surg J. 2008;28(1):17-23. 3. JUVÉDERM® Ultra Plus XC Directions for Use, 2016.
JUVÉDERM® INJECTABLE GEL FILLERS INDICATIONS AND IMPORTANT SAFETY INFORMATION
The JUVÉDERM® Collection of Fillers includes JUVÉDERM® VOLUMA™ XC, JUVÉDERM® VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, JUVÉDERM® Ultra XC, and JUVÉDERM® VOLBELLA™ XC. JUVÉDERM® VOLUMA™ XC is for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related mid-face volume deficit and for augmentation of the chin region to improve the chin profile in adults over the age of 21. JUVÉDERM® VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC are for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). JUVÉDERM® Ultra XC is also for injection into the lips and perioral area for lip augmentation in adults over the age of 21. JUVÉDERM® VOLBELLA™ XC is for injection into the lips for lip augmentation and for correction of perioral rhytids in adults over the age of 21.
JUVÉDERM® Collection of Fillers Important Information
INDICATIONS

JUVÉDERM® VOLUMA™ XC is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face and for augmentation of the chin region to improve the chin profile in adults over the age of 21.


JUVÉDERM® VOLLURE™ XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.


JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).


JUVÉDERM® VOLBELLA™ XC injectable gel is indicated for injection into the lips for lip augmentation and for correction of perioral rhytids in adults over the age of 21.


JUVÉDERM® Ultra XC injectable gel is indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.
WARNINGS
•Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
•Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled
PRECAUTIONS
•To minimize the risk of potential complications, these products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy and product use in indicated areas
•The potential risks of soft-tissue injections should be discussed with patients prior to treatment to ensure they are aware of signs and symptoms of complications
•The safety and effectiveness for the treatment of anatomic regions other than the mid-face, chin, and prejowl sulcus regions with JUVÉDERM® VOLUMA™ XC; facial wrinkles and folds with JUVÉDERM® VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM® Ultra XC; and the lips and perioral area with JUVÉDERM® VOLBELLA™ XC and JUVÉDERM® Ultra XC have not been established in controlled clinical studies
•The safety for use of these products during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
•The safety for use of JUVÉDERM® VOLUMA™ XC has been established in patients between 35 and 65 years of age in cheek augmentation and for patients between 22 and 80 years of age for chin augmentation
•The safety for use of JUVÉDERM® Ultra Plus XC and JUVÉDERM® Ultra XC in patients under 18 years, and JUVÉDERM® VOLLURE™ XC and JUVÉDERM® VOLBELLA™ XC in patients under 22 years, has not been established
•As with all transcutaneous procedures, dermal filler implantation carries a risk of infection
•Use dermal fillers with caution in patients on immunosuppressive therapy
•Patients who are using products that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
•Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events
•The safety for use of JUVÉDERM® VOLUMA™ XC injectable gel in patients with very thin skin in the mid-face has not been established
•The safety of JUVÉDERM® VOLUMA™ XC with cannula for cheek augmentation has not been established in patients with Fitzpatrick Skin Types V and VI
•JUVÉDERM® VOLUMA™ XC was not evaluated in subjects with significant skin laxity of the chin, neck, or jaw in the chin augmentation study
•The effect of JUVÉDERM® VOLUMA™ XC injection into the chin on facial hair growth has not been studied
•Patients may experience late onset nodules with use of dermal fillers including JUVÉDERM® VOLUMA™ XC
•Patients may experience late onset adverse events with use of dermal fillers







ADVERSE EVENTS
The most commonly reported side effects for JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM® VOLBELLA™ XC, dryness was also reported. The majority were mild or moderate in severity. For JUVÉDERM® VOLUMA™ XC, most resolved within 2 to 4 weeks. For JUVÉDERM® VOLLURE™ XC, JUVÉDERM® Ultra Plus XC, or JUVÉDERM® Ultra XC, most resolved within 14 days; and for JUVÉDERM® VOLBELLA™ XC, most resolved within 30 days.
To report an adverse reaction with any product in the JUVÉDERM® Collection, please call Allergan at 1-800-433-8871. Please visit JuvedermDFU.com for more information.
Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

Privacy Statement | California Privacy Policy | Terms of Use
© 2020 Allergan. All rights reserved. All trademarks are the property of their respective owners.
hcp.Juvederm.com JUV106549-v5 08/20 007232

This website uses cookies and other technologies to personalize content and to show you more personalized ads (for example, Google Ads and Facebook) on this and other websites, as well as provide you with social media features on this website (such as, Facebook, Twitter, LinkedIn). Read More By clicking "Accept" you understand that you are directing Allergan to disclose your personal information, including internet tracking data (like cookies and the IP address you used to access this website), to these third parties for the purposes stated above. You can still use this website if you do not click "Accept," but your experience may be different. For more information, including a list of the categories of third parties to whom we disclose your personal information, please refer to our California Privacy Policyopens in a new window or for additional options please check your browser’s settings. Read Less

Accept
×